Emiten PYFA Gelar RUPST untuk Tahun Buku 2024, serta Tetapkan Jajaran Direksi dan Dewan Komisaris Baru
Jakarta, 18 June 2025 — PT Pyridam Farma Tbk (Stock Code: PYFA), a publicly listed pharmaceutical company, has held its Annual General Meeting of Shareholders (AGMS) for fiscal year 2024 on Wednesday, June 18, 2025. In this AGMS, the pharmaceutical issuer now known under the PYFAGROUP brand discussed six agenda items reflecting the 2024 performance review and PYFA’s strategic steps to strengthen its organizational structure and future corporate development direction.
The six agenda items discussed in the AGMS were as follows:
Approval of the Annual Report and Sustainability Report for the 2024 Fiscal Year;
Determination of the use of the Company’s net profit/loss for fiscal year 2024;
Determination of remuneration for members of the Board of Directors and Board of Commissioners for fiscal year 2025;
Appointment of a Public Accounting Firm to audit the financial statements for fiscal year 2025;
Report on the realization of fund usage from the Sustainable Public Offering Bonds, Rights Issue, and Series 1 Warrant Issuance;
Approval of changes to the composition of the Company’s management.
The main focus of this year’s AGMS was the appointment of the new Board of Directors and Board of Commissioners of PYFA for a five-year term in accordance with PYFA’s Articles of Association. This refreshment is part of PYFA’s long-term commitment to strengthening leadership foundations and building a more adaptive organizational structure in response to the dynamics of the pharmaceutical industry.
“Changes in management structure are not merely a rotation, but part of a strategic transformation step to accelerate growth and enhance PYFA’s development as a globally competitive pharmaceutical company,” said Mr. Lee Yan Gwan, President Director of PYFA.
Two professionals officially appointed to strengthen the Board of Directors in this AGMS are Antes Eko Prasetio and Sinta Lestari Ningsih. The newly approved management structure by the shareholders is as follows:
Board of Directors:
President Director: Lee Yan Gwan
Director: Yenfrino Gunadi
Director: Bedjo Stefanus
Director: Antes Eko Prasetio
Director: Sinta Lestari Ningsih
Board of Commissioners:
President Commissioner: Robby Yulianto
Commissioner: Widjanarko Brotosaputro
Independent Commissioner: Maura Linda Sitanggang
Independent Commissioner: Charles D. Marpaung
Antes Eko Prasetio is an executive with more than 15 years of experience in the pharmaceutical and healthcare industry, both in national and multinational settings. He has held strategic roles at several renowned companies including PT Roche Indonesia, PT GlaxoSmithKline, Johnson & Johnson Indonesia, and Mundipharma Healthcare Indonesia. His last position was Commercial Director for the Ethical & Consumer Healthcare division (Betadine). Joining PYFA as Chief Commercial Officer, his experience in driving business growth and strengthening distribution channels is expected to support the continued expansion of PYFAGROUP’s portfolio.
Meanwhile, Sinta Lestari Ningsih, officially appointed as Director, brings over 15 years of experience in finance, accounting, and risk management across multiple industries including finance, music, and fintech. She previously worked at the accounting firm KPMG, and held strategic roles at PT Warner Music Indonesia and PT Visionet Internasional (OVO). Since 2021, she has served as VP of Finance, Accounting, and Tax at PYFA. Her strong track record and deep understanding of corporate financial systems will reinforce the company’s financial foundation in executing sustainable growth strategies.
With these two new figures joining the Board of Directors, PYFA is optimistic about accelerating the execution of its business strategies, enhancing cross-functional management effectiveness, and maintaining the ongoing transformation of the company. Through the approved leadership restructuring and strategic policy direction from the AGMS, PYFA affirms its commitment to continuously improving performance and competitiveness through a more adaptive, efficient organization focused on creating long-term added value for shareholders and stakeholders.
About PYFAGROUP
PT Pyridam Farma Tbk (Stock Code: PYFA), known under the brand PYFAGROUP, is one of the publicly listed companies in the pharmaceutical sector on the Indonesia Stock Exchange. PYFA’s business units include supplements and prescription drugs in various forms such as tablets, capsules, creams, and injections. PYFA is the controlling shareholder of several subsidiaries, including PT Holi Pharma based in Cimahi, West Java; PT Ethica Industri Farmasi with manufacturing facilities in Cikarang, West Java; and Probiotec Pty Ltd based in Australia.
Media Contact:
Leilanie Nadia Kusuma
Website: www.pyfa.co.id
Email: corcomm@pyfa.co.id
